During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The study aims to determine if evolocumab can reduce the risk of death from coronary heart disease, heart attacks, and strokes in people receiving standard cholesterol-lowering therapy. The medication is given as an injection under the skin using a pre-filled pen that contains 140 mg of evolocumab.

During the study, participants will receive either evolocumab injections or placebo injections. The treatment period lasts for 72 weeks, during which participants will continue their usual cholesterol-lowering medications. The study will track various heart-related health events, including arterial revascularization (procedures to restore blood flow in blocked arteries) and death from heart-related causes.

Participants in the study will be those who have been recently hospitalized with heart failure and have a certain level of heart function, measured by something called the ejection fraction. This is a percentage that shows how well the heart is pumping blood. The study will involve taking the medication or placebo for a period of time, and researchers will monitor the participants for any heart-related events or changes in their condition.

The study aims to gather information on the effectiveness and safety of finerenone in managing heart failure symptoms and improving survival rates. By comparing the outcomes of those taking finerenone with those taking a placebo, researchers hope to better understand the potential benefits of this treatment for patients with heart failure.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

The purpose of the study is to evaluate the effectiveness and safety of asundexian in reducing the risk of ischemic strokes. Participants in the study will be randomly assigned to receive either asundexian or a placebo. The study will monitor the time it takes for participants to experience another ischemic stroke or any major bleeding events, which are significant bleeding episodes that can occur in the body. The trial will also look at other outcomes, such as the occurrence of any type of stroke, heart-related events, and overall survival rates.

Throughout the study, participants will take the medication orally in the form of a film-coated tablet. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, ensuring unbiased results. The study aims to provide valuable information on whether asundexian can offer better protection against strokes compared to current treatments.

The purpose of the study is to determine if Inclisiran can reduce the risk of serious heart problems, such as heart attacks, strokes, or the need for urgent procedures to restore blood flow to the heart. The study will be conducted over a period of time, during which participants will receive regular injections of the medication or placebo and will be monitored for any heart-related events. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants will be closely observed throughout the study to track the time it takes for any major heart events to occur. The study will also look at other outcomes, such as the time to cardiovascular death and overall mortality. The goal is to gather information on the safety and effectiveness of Inclisiran in preventing heart-related issues in people who are at high risk but have not yet had a major cardiovascular event.